Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)
| العنوان: | Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG) |
|---|---|
| المؤلفون: | Angelika Eggert, Nadezhda Fedorovna Bobrova, Madlen Reschke, Doris Hadjistilianou, Hatice Tuba Atalay, Annette C. Moll, Martin Ebinger, Eva Biewald, Katarzyna Pawinska-Wasikowska, Catriona Duncan, Hayyam Kiratli, Karel Svojgr, David Garcia Aldana, François Doz, Ines B Brecht, Francis L. Munier, Constantino Sábado Álvarez, Erika Maka, Yelena Diarra, Floor Abbink, Nikolaos E. Bechrakis, Beate Timmermann, Nathalie Cassoux, Tomáš Kepák, Maja Beck Popovic, Petra Ritter-Sovinz, Vicktoria Vishnevskia-Dai, Shani Caspi, Guillermo Chantada, Guilherme Castela, Artur Klett, Olga Rutynowska-Pronicka, Enrico Opocher, Ida Russo, Sabine Dittner-Moormann, Jelena Rascon, Isabelle Aerts, Helen Jenkinson, Petra Ketteler, Sonsoles San Roman Pacheco |
| المساهمون: | Pediatric surgery, CCA - Cancer Treatment and quality of life, Ophthalmology, APH - Quality of Care, APH - Health Behaviors & Chronic Diseases, ACS - Diabetes & metabolism, Institut Català de la Salut, [Dittner-Moormann S] Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany. [Reschke M] Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany. [Abbink FCH] Amsterdam UMC, Location VU University Medical Centre, Amsterdam, The Netherlands. [Aerts I] Institut Curie, PSL Research University and University of Paris, Paris, France. [Atalay HT] Gazi University School of Medicine, Ankara, Turkey. [Fedorovna Bobrova N] Filatov Eye Institute Odessa, Odessa, Ukraine. [Sábado Álvarez C] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | PEDIATRIC BLOOD & CANCER r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Fundació Sant Joan de Déu r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu instname Pediatric Blood and Cancer, 68(6):e28963. Wiley-Liss Inc. Scientia Pediatric blood & cancer, Hoboken : Wiley, 2021, vol. 68, iss. 6, art. no. e28963, p. [1-9] Dittner-Moormann, S, Reschke, M, Abbink, F C H, Aerts, I, Atalay, H T, Fedorovna Bobrova, N, Biewald, E, Brecht, I B, Caspi, S, Cassoux, N, Castela, G, Diarra, Y, Duncan, C, Ebinger, M, Garcia Aldana, D, Hadjistilianou, D, Kepák, T, Klett, A, Kiratli, H, Maka, E, Opocher, E, Pawinska-Wasikowska, K, Rascon, J, Russo, I, Rutynowska-Pronicka, O, Sábado Álvarez, C, Pacheco, S S R, Svojgr, K, Timmermann, B, Vishnevskia-Dai, V, Eggert, A, Ritter-Sovinz, P, Bechrakis, N E, Jenkinson, H, Moll, A, Munier, F L, Popovic, M B, Chantada, G, Doz, F & Ketteler, P 2021, ' Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG) ', Pediatric Blood and Cancer, vol. 68, no. 6, e28963 . https://doi.org/10.1002/pbc.28963Test |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Oncology, genetic structures, medicine.medical_treatment, Medizin, childhood cancer, chemotherapy, terapéutica::tratamiento combinado [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], metastasis, 0302 clinical medicine, Risk Factors, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, biomarker, Child, Retinoblastoma, Extraocular Retinoblastoma, Hematology, Prognosis, Combined Modality Therapy, RB1 gene, 3. Good health, Europe, Chemotherapy, Adjuvant, Child, Preschool, 030220 oncology & carcinogenesis, Resection margin, neoplasias::neoplasias::neoplasias::neoplasias::neoplasias por localización::neoplasias del ojo::neoplasias de la retina::retinoblastoma [ENFERMEDADES], Adjuvant, medicine.medical_specialty, Retinal Neoplasms, Enucleation, técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Enquestes, Intraocular Retinoblastoma, Eye Enucleation, 03 medical and health sciences, Internal medicine, medicine, Adjuvant therapy, Humans, Neoplasms::Neoplasms::Neoplasms::Neoplasms::Neoplasms by Site::Eye Neoplasms::Retinal Neoplasms::Retinoblastoma [DISEASES], radiotherapy, Retina - Càncer - Radioteràpia, business.industry, técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], medicine.disease, eye diseases, Retina - Càncer - Quimioteràpia, Therapeutics::Combined Modality Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Radiation therapy, Pediatrics, Perinatology and Child Health, Radiotherapy, Adjuvant, sense organs, Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], business, 030215 immunology |
| الوصف: | Chemotherapy; Childhood cancer; Radiotherapy Quimioterapia; Cáncer infantil; Radioterapia Quimioteràpia; Càncer infantil; Radioteràpia Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Results Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers. Open access funding enabled and organized by Projekt DEAL. |
| وصف الملف: | application/pdf |
| تدمد: | 1545-5017 1545-5009 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2452008a1f17db6cc1a00716a9b3562dTest https://doi.org/10.1002/pbc.28963Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2452008a1f17db6cc1a00716a9b3562d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15455017 15455009 |
|---|